8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2013

Orthofix International N.V.

(Exact name of Registrant as specified in its charter)

Curaçao	0-19961	N/A
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

7 Abraham de Veerstraat Curaçao	N/A
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 011-59-99-465-8525

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Promotion of Emily Buxton to Chief Financial Officer and Related Compensation Arrangements

On April 1, 2013, the Board of Directors (the “Board”) of Orthofix International N.V. (the “Company”) promoted Emily Buxton to the position of Chief Financial Officer of the Company. Ms. Buxton had previously been serving as the Company’s Interim Chief Financial Officer and Chief Financial Officer, Orthopedic Global Business Unit. In connection with her promotion, the Compensation Committee of the Board has approved an increase in Ms. Buxton’s base salary to $325,000 and set her target bonus under the Company’s Annual Incentive Plan at an amount equal to sixty percent (60%) of her base salary.

Item 7.01. Regulation FD Disclosure.

On April 4, 2013, the Company issued a press release regarding the matters described in Item 5.02. That press release is furnished herewith as Exhibit 99.1.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release, dated April 4, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Orthofix International N.V.
By:	/s/ Jeffrey M. Schumm
	Jeffrey M. Schumm Senior Vice President, General Counsel and Corporate Secretary

Date: April 5, 2013

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release, dated April 4, 2013.

EX-99.1

Exhibit 99.1

Orthofix International Appoints Emily Buxton as Chief Financial Officer

LEWISVILLE, Texas – April 4, 2013 (BUSINESS WIRE) – Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today that it has appointed Emily Buxton as its Chief Financial Officer. Ms. Buxton had been serving as the Company’s Interim Chief Financial Officer since October 2012.

President and Chief Executive Officer Brad Mason said, “I am delighted to announce the appointment of Emily to this critical position, particularly at this time in Orthofix’s history when we are so well positioned for the future. It will be my pleasure to work side by side with her and the rest of the executive team as we explore the many opportunities we have to define the Orthofix of tomorrow. Emily has successfully served in various financial roles of increasing responsibility since joining Orthofix in 2003. I believe her proven track record in financial management, global business experience, and strong understanding of every aspect of the Company will help take us to the next level in driving value for our healthcare partners and shareholders.”

Ms. Buxton joined Orthofix’s corporate finance group in 2003 as a Senior SEC and Consolidations Accountant. After advancing to the position of Vice President, Controller, she served as Chief Financial Officer of Global Orthopedics for Orthofix from 2010 to the time of her appointment as Interim Chief Financial Officer. Prior to joining Orthofix, Ms. Buxton worked for two large public companies in Securities and Exchange Commission reporting and prior to that she worked in public accounting. She received her Bachelors of Arts degree in Accounting from Columbia College in Columbia, SC.

About Orthofix:

Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Orthofix’s products are widely distributed around the world to surgeons and patients via Orthofix’s sales representatives and its subsidiaries, and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, and Texas Scottish Rite Hospital for Children. For more information about Orthofix, please visit www.orthofix.com.

Contact:

Mark Quick

Director of Investor Relations and Business Development

markquick@orthofix.com

214-937-2924

Source:

Orthofix International N.V.